Physician profile
Aaron M Smith
NPI 1245673557
$6,779.02
in general payments reported to CMS, 2019-2025
25 companies · $1,004 in 2025
The $1,004 reported for 2025 was more than what 82% of Otolaryngology/Facial Plastic Surgery providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,128 · 2020: $735 · 2021: $1,222 · 2022: $521 · 2023: $459 · 2024: $711 · 2025: $1,004.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,173.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $2,834.05 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $935.12 | 2019-2025 | Dupixent |
| Genzyme Corporation | $729.32 | 2021-2025 | |
| Optinose US, INC. | $392.82 | 2019-2025 | |
| Medtronic, INC. | $308.44 | 2021-2024 | Propel, Ligasure |
| Smith+Nephew, INC. | $230.53 | 2019-2024 | Tula |
| Integra Lifesciences Corporation | $223.02 | 2022-2025 | Relieva Spinplus Nav, Trudi Probe, Inspira Air |
| Glaxosmithkline, LLC. | $194.51 | 2023-2025 | Nucala |
| Hologic Sales and Service, LLC | $144.44 | 2022 | |
| Inspire Medical Systems, INC. | $140.69 | 2025 | Inspire |
| Astrazeneca Pharmaceuticals Lp | $125.00 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $100.07 | 2023 | Caldolor |
| Lucid Diagnostics INC. | $91.82 | 2022 | |
| Kls-Martin L.P. | $78.20 | 2019 | |
| Organogenesis INC. | $60.69 | 2023 | Puraply |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $33.88 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Paratek Pharmaceuticals, INC. | $22.44 | 2025 | Xhance |
| Intersect Ent, INC. | $22.36 | 2020 | |
| Allergan, INC. | $21.00 | 2019 | |
| Merck Sharp & Dohme LLC | $20.34 | 2023 | |
| Hikma Pharmaceuticals USA | $16.05 | 2023 | Ryaltris |
| Alk-Abello, INC | $15.25 | 2021 | |
| Acacia Pharma INC | $13.83 | 2021 | |
| Medtronic USA, INC. | $12.89 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $12.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.